Search

everythinglearnresearchcommunity

for

Search:↓

Upadacitinib is safe and effective for treating alopecia areata and atopic dermatitis in children.

Tofacitinib helped psoriasis but not alopecia universalis, needing more research.

Thiopurines help treat IBD but require genetic testing to avoid side effects.

A humanized IL-2 fusion protein boosts T regulatory cells and helps control hair loss in Alopecia Areata.

Overexpression of IKZF1 and Ikaros causes hair loss in mice similar to alopecia areata.

Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.

Sorafenib may cause hair loss in a way similar to alopecia areata.

Cold caps and certain drugs may help prevent or reduce hair loss from chemotherapy, but more research is needed.

AS101 reduces hair loss from chemotherapy.

Tumor proteins can both promote and suppress cancer, depending on the situation.

Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.

Potassium iodide prevents hair loss and reduces toxicity from thallium acetate.

Tofacitinib may help regrow hair in alopecia areata patients.

A potential treatment for atopic dermatitis could be to increase PADI1 expression to improve skin barrier function.

Finasteride and dutasteride reduce unwanted movements from Parkinson's disease treatment by normalizing certain brain signals.

LY191704 is a compound that effectively blocks a specific enzyme involved in hormone conversion and could help treat enlarged prostate and hair loss.

Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.

New inhibitors may reduce gut toxicity from cancer drugs.

Turning off a specific gene in stem cells speeds up skin healing by helping cells move better.

Patients and oncologists prioritize survival benefits, while payers focus on treatment costs.

The inhibitor affects androgen metabolism but not ovarian function.

Antizyme slows skin tumor growth by reducing cell growth in mice.

New targeted immunotherapies are improving treatment for inflammatory skin diseases.

IL-27 may help prevent hair loss by creating immune-suppressing cells.

Baricitinib effectively improved skin and hair conditions in a patient with alopecia areata and atopic dermatitis.

The topical inhibitor CUR61414 was not effective in treating basal cell carcinoma in human trials.

A 14-year-old girl with severe hair loss regrew her hair using upadacitinib.

Potassium channel openers show promise for treating heart disease and other conditions, but more research is needed to fully understand their effects and safety.

Drugmakers are optimistic about targeting the Wnt pathway for new treatments despite past challenges.

Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.